Answers are grounded in this paper and cite their sources.
The spread of antimicrobial resistance among gram-negative bacilli, particularly within Enterobacteriaceae and non-fermentative gram-negative bacilli, poses a serious and escalating threat to global public health. Colistin, a cationic antimicrobial peptide, remains a last-line treatment for infections caused by multidrug-resistant gram-negative bacteria. However, the global dissemination of the plasmid-encoded colistin resistance gene mobilized colistin resistance-1 ( mcr-1 ) has contributed to increasing cases of colistin resistance and threatens global health. Nanobodies offer advantages, including high affinity, stability, and small size. Here, we isolated anti-MCR-1.1 nanobodies from a phage-display library and evaluated their potential to restore colistin efficacy. The periplasmic catalytic domain of MCR-1.1 was purified by affinity chromatography and used to immunize alpacas, resulting in the construction of a phage-displayed nanobody library against MCR-1.1 with a size of 5.8 × 10⁸ CFU. After biopanning, several anti-MCR-1.1 nanobodies specific for the periplasmic catalytic domain of MCR-1.1 were successfully isolated. Among them, high-affinity nanobodies Nb7, Nb12, Nb24, and Nb30 were selected in vitro , with Nb30 demonstrating promising activity. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. In combination with colistin, Nb30-1 effectively inhibited the growth of colistin-resistant, MCR-1.1-expressing laboratory Escherichia coli BL21(DE3), as determined by the growth dynamics curve. Molecular docking analysis revealed the binding interactions between Nb30/Nb30-1 and the MCR-1.1 protein, and affinity measurements confirmed their high binding affinity for the MCR-1.1 antigen. Given the exquisite conservation of key catalytic residues and the epitope recognized by Nb30-1 across MCR-1 variants, Nb30-1 represents a promising macromolecular adjuvant strategy to overcome MCR-1-mediated resistance. IMPORTANCE The escalating use of antibiotics has driven a global rise in antibiotic resistance, underscoring an urgent need for adjuvants that can restore the susceptibility of drug-resistant bacteria. In this study, we isolate anti-MCR-1 nanobodies from a phage-display library and evaluate their potential to restore colistin efficacy. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. These findings suggest that engineered anti-MCR-1 nanobodies, particularly Nb30-1, represent a promising therapeutic strategy to combat MCR-1-positive colistin-resistant bacterial infections by resensitizing bacteria to colistin.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: